文献速递乳腺癌

ESR1 F404突变与ESR1突变乳腺癌中氟维司群获得性耐药

ESR1 F404 Mutations and Acquired Resistance to Fulvestrant in ESR1-Mutant Breast Cancer.
PubMed 文献 · Cancer Discov · 2024-01-01

血浆MATCH A队列(NCT03182634)研究氟维司群在循环肿瘤DNA中携带活化ESR1突变患者的活性。基线ESR1 Y537S与不良结局相关,Y537C与良好结局相关。基线及治疗结束ctDNA测序(n=69)显示3/69(4%)患者获得新发ESR1 F404突变(F404L、F404I、F404V),与活化突变呈顺式。体外分析显示单F404L、E380Q、D538G模型对氟维司群敏感性降低,而复合突变D538G+F404L和E380Q+F404L耐药。多种口服ERα降解剂对复合突变模型有活性。

要点

  • 血浆MATCH A队列中3/69(4%)患者获得ESR1 F404突变,与活化突变呈顺式。
  • 基线ESR1 Y537S与不良结局相关,Y537C与良好结局相关。
  • 单F404L、E380Q、D538G模型对氟维司群敏感性降低,复合突变D538G+F404L和E380Q+F404L耐药。

核心结论

  • 新发F404 ESR1突变可能与预先存在的活化ESR1突变联合导致对氟维司群的明显耐药。
  • ER配体结合域的新突变组合可能导致药物特异性耐药,强调类似药物特异性突变可能影响开发中的口服ER降解剂的疗效。

研究设计与样本

  • 血浆MATCH A队列(NCT03182634)研究氟维司群在循环肿瘤DNA中携带活化ESR1突变患者中的活性。
  • 对基线和治疗结束ctDNA样本进行测序(n=69)。
  • 进行计算机模拟建模和体外分析。

主要发现

  • 基线ESR1 Y537S与不良结局相关,Y537C与良好结局相关。
  • 3/69(4%)患者获得新发ESR1 F404突变(F404L、F404I、F404V),与活化突变呈顺式。
  • 计算机模拟建模显示ESR1 F404通过π-堆积键参与氟维司群与雌激素受体α(ERα)结合,突变破坏该键。
  • 体外分析显示单F404L、E380Q、D538G模型对氟维司群敏感性降低,而复合突变D538G+F404L和E380Q+F404L耐药。
  • 多种口服ERα降解剂对复合突变模型有活性。

关键数值与推荐

  • 3/69(4%)患者获得新发ESR1 F404突变(F404L、F404I、F404V)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Fulvestrant is used to treat patients with hormone receptor-positive advanced breast cancer, but acquired resistance is poorly understood. PlasmaMATCH Cohort A (NCT03182634) investigated the activity of fulvestrant in patients with activating ESR1 mutations in circulating tumor DNA (ctDNA). Baseline ESR1 mutations Y537S are associated with poor outcomes and Y537C with good outcomes. Sequencing of baseline and EOT ctDNA samples (n = 69) revealed 3/69 (4%) patients acquired novel ESR1 F404 mutations (F404L, F404I, and F404V), in cis with activating mutations. In silico modeling revealed that ESR1 F404 contributes to fulvestrant binding to estrogen receptor-alpha (ERα) through a pi-stacking bond, with mutations disrupting this bond. In vitro analysis demonstrated that single F404L, E380Q, and D538G models were less sensitive to fulvestrant, whereas compound mutations D538G + F404L and E380Q + F404L were resistant. Several oral ERα degraders were active against compound mutant models. We have identified a resistance mechanism specific to fulvestrant that can be targeted by treatments in clinical development. SIGNIFICANCE: Novel F404 ESR1 mutations may be acquired to cause overt resistance to fulvestrant when combined with preexisting activating ESR1 mutations. Novel combinations of mutations in the ER ligand binding domain may cause drug-specific resistance, emphasizing the potential of similar drug-specific mutations to impact the efficacy of oral ER degraders in development. This article is featured in Selected Articles from This Issue, p. 201.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Kingston B, Pearson A, Herrera-Abreu MT, et al. ESR1 F404 Mutations and Acquired Resistance to Fulvestrant in ESR1-Mutant Breast Cancer. Cancer Discov. 2024. PMID: 37982575. doi:10.1158/2159-8290.CD-22-1387

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。